Kite submits MAA for CAR T therapy
Kite Pharma Inc. (NASDAQ:KITE) submitted an MAA to EMA for chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (KTE-C19) to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma and primary mediastinal B cell lymphoma in patients ineligible for autologous stem cell transplantation (ASCT). The company said the application is the first CAR T cell therapy submitted in Europe.
Axicabtagene ciloleucel comprises autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19. The therapy has PRIority MEdicines (PRIME) designation from EMA for DLBCL...
BCIQ Company Profiles
BCIQ Target Profiles